Hereditary transthyretin amyloidosis in Sweden: Comparisons between a non-endemic and an endemic region. (2nd October 2022)

• Record Type: Journal Article
• Authors: Samuelsson, Kristin; Jovanovic, Ana; Egervall, Karl; Anan, Intissar; Wixner, Jonas; Press, Rayomand
• Is Part Of: Amyloid. Volume 29:Number 4(2022)
• Page Start: 220
• Page End: 227
• Publication Date: 2022-10-02
• Subjects: Amyloidosis -- amyloid polyneuropathy -- diagnosis delay -- endemic -- transthyretin; Amyloidosis -- Periodicals; 616.3995
• DOI: 10.1080/13506129.2022.2065191
• Languages: English
• ISSNs: 1350-6129

Abstract

Abstract: Introduction: Hereditary transthyretin amyloidosis (ATTRv) is endemic in northern Sweden (Västerbotten). The awareness of ATTRv amyloidosis is lower in Stockholm, a non-endemic region in Sweden. The aim of this study was to compare the possible differences in diagnostic delay, disease phenotypes, treatment and survival between a non-endemic and an endemic region in Sweden. Methods: The in- and outpatient diagnosis registry at the Department of Neurology at Karolinska University Hospital and the Amyloidosis Centre at University Hospital of Umeå were used to identify patients between January 2006 and November 2017. Results: In total, 21 patients in Stockholm and 134 patients in Västerbotten were included. The time between symptom onset to time-point of diagnosis was significantly longer in Stockholm vs Västerbotten. This corresponded to a longer median time between first visit at amyloidosis centre to time-point of diagnosis in Stockholm vs in Västerbotten. The most common reason for a diagnostic delay was negative tissue biopsies. Conclusion: There was a diagnostic-, but no patient-delay in non-endemic Stockholm vs endemic Västerbotten. Despite a more severe neuropathic phenotype in Stockholm at the onset, the systemic affection over the course of disease and of survival seems not to be influenced by the diagnosis delay in Stockholm.